Back to results
US 11,453,720 B2Granted
Anti-TIGIT antigen-binding proteins and methods of use thereof
AssigneePotenza Therapeutics, Inc.
InventorsNels P. Nielson, Daniel Hicklin, Cynthia Seidel-Dugan, William Winston, Heather Brodkin, Jose-Andres Salmeron-Garcia, Christopher James Nirschl, Philipp Steiner
Life of this patent
Estimating the term…
Abstract
Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
Claims21
A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of:
- (i) an antibody or antigen binding fragment thereof comprising
- a) a VH sequence of SEQ ID NO:
- 4 and a VL sequence of SEQ ID NO:
- 25;
- b) a VH sequence of SEQ ID NO:
- 5 and a VL sequence of SEQ ID NO:
- 25;
- c) a VH sequence of SEQ ID NO:
- 6 and a VL sequence of SEQ ID NO:
- 25;
- d) a VH sequence of SEQ ID NO:
- 7 and a VL sequence of SEQ ID NO:
- 25;
- e) a VH sequence of SEQ ID NO:
- 8 and a VL sequence of SEQ ID NO:
- 25;
- f) a VH sequence of SEQ ID NO:
- 9 and a VL sequence of SEQ ID NO:
- 26;
- g) a VH sequence of SEQ ID NO:
- 10 and a VL sequence of SEQ ID NO:
- 26;
- h) a VH sequence of SEQ ID NO:
- 11 and a VL sequence of SEQ ID NO:
- 26;
- i) a VH sequence of SEQ ID NO:
- 12 and a VL sequence of SEQ ID NO:
- 26;
- j) a VH sequence of SEQ ID NO:
- 13 and a VL sequence of SEQ ID NO:
- 26;
- k) a VH sequence of SEQ ID NO:
- 14 and a VL sequence of SEQ ID NO:
- 26;
- l) a VH sequence of SEQ ID NO:
- 15 and a VL sequence of SEQ ID NO:
- 26;
- m) a VH sequence of SEQ ID NO:
- 16 and a VL sequence of SEQ ID NO:
- 27;
- n) a VH sequence of SEQ ID NO:
- 17 and a VL sequence of SEQ ID NO:
- 27;
- o) a VH sequence of SEQ ID NO:
- 18 and a VL sequence of SEQ ID NO:
- 27;
- p) a VH sequence of SEQ ID NO:
- 19 and a VL sequence of SEQ ID NO:
- 27;
- q) a VH sequence of SEQ ID NO:
- 20 and a VL sequence of SEQ ID NO:
- 27;
- r) a VH sequence of SEQ ID NO:
- 21 and a VL sequence of SEQ ID NO:
- 27;
- s) a VH sequence of SEQ ID NO:
- 22 and a VL sequence of SEQ ID NO:
- 28;
- t) a VH sequence of SEQ ID NO:
- 23 and a VL sequence of SEQ ID NO:
- 28;
- or
- u) a VH sequence of SEQ ID NO:
- 24 and a VL sequence of SEQ ID NO:
- 28;
- and
- (ii) one or more additional immunotherapeutic agents selected from the group consisting of:
- a) an immunotherapeutic agent that blocks signaling of an inhibitory receptor of an immune cell or a ligand thereof;
- and
- b) an immunotherapeutic agent that modulates signaling of a co-stimulatory receptor.
67 more elements
Dependencies are inferred from the claim text.